Emberton M. The hallmarks of BPH progression and risk factors. Eur Urol. 2003;(2):2–7.
2.
Jacobsen Sj G, Cj G, Hd. Oesterling jE, Lieber MM. New diagnostic and treatment guidelines for benign prostatic hyperplasia. arch Intern Med. 1995;477–81.
3.
Nickal Jc, Fradet Y, Rc B. Pommerville Pj, Perreauly jP, afridi sK et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PrOsPECT study). CMaj. 1996;1215–9.
4.
Roehrborn C, Mcnicholas T. The management of prostatic obstruction: haw to determine the best options? Eur Urol. 2003;(2):13–9.
5.
Mebust W, Holtgrewe H, Cockett, Peters P. Writing Comitee, the american Urological association. Transurethral prostatectomy: immediate and postoperatrive complications. Cooperative study of 13 participating institutions evaluating 3.885 patients. Urol. 1989;243–9.
6.
Gupta N, Kumar R. Transurethral vapor resection of prostate is a good alternative for prostate > 70 g. j Endourol. 2007;(12):1543–6.
7.
Carlin B. Bodner dr, spinnak jP, resnik MI. role of finasterid in treatment of recurrent hematuria secondary to benign prostatic hyperplasia. Prostate. 1997;180–2.
8.
Pj P, Miller M. The effect of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report. Urol. 1995;1779–82.
9.
Sieber Pr, Rommel F, Huffnagle H, Ve, Harpster L. The treatment of gross hematuria secondary to prostatic bleeding with finasteride. Urol. 1998;1232–3.
10.
Connell M. 5 alpha-reductase inhibitors. adv Protein Chem. 2001;143–8.
11.
Hagerty Ja, Ginsberg P, Harmon Jd H, Rc. Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of the prostate. Urology. 2000;684–7.
12.
Lund L, Kl EJ, Torring N, Nielsen Je. Impact of finasteride treatment of perioperative bleeding before transurethral resection of the prostate: a prospective randomized study. scan j Urol Nephrol. 2005;160–2.
13.
Gj G, Bruskewitz R, Imperato-Mcginley J, Walsh P, Mcconnell Jd. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride study Group. N Engl j Med. 1992;1185–91.
14.
Stoner E. The clinical effects of 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride study Group. Urol. 1992;1292–302.
15.
H, Dr T, Foster M. Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of the role of finasteride for decreasing operative blood loss. Urol. 2002;2024–6.
16.
Bostwick Dg, Coner W, Denis L, Jones G, Murphy P, G. The association of benign prostatic hyperplasia and cancer of he prostate. Cancer. 1992;291–301.
17.
Patel A F, Gj, Guttierrez-Aceres J, Andrade-Perez F. Transurethral electrovaporization and vapour-rescetion of the prostate: an appraisal of possible electrosurgical after natives to regular loop resection. BjU Int. 2000;202–10.
Citation
Copyright
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
